Cloud-based SaaS Product Turns Data Centers and Software Applications from Grid Consumers to Grid Partners Helping to Decarbonize and Stabilize the Electricity Supply
Read More
"President Trump is facing an impossible landscape created by years of regulatory neglect. We built a federally compliant, pharmaceutical grade marijuana medicine to bring order to that chaos. MMJ offers the President a path that respects the law, protects patients, and restores integrity to cannabinoid science."
-Duane Boise, President & CEO, MMJ International Holdings
They provided risk projections for managers to choose, the chosen 20% TAC reduction yields 0% probability of overfishing
Under the 2020 ERP definitions, Atlantic menhaden are not overfished and overfishing is not occurring. For 2023, fecundity is on the order of 1.2 quadrillion eggs (above the ERP fecundity threshold but below the target) and fishing mortality is about 0.26 (above the ERP F-target but still below the ERP F-threshold). The overview also makes clear there is no single "right" ERP; selecting ERP targets and thresholds is a management choice that balances objectives for menhaden and their predators.
The 2025 single-species update applied a lower estimate of natural mortality (M). That change lowers the back-calculated biomass, fecundity, and recruitment across the time series and raises the corresponding fishing mortality (F) estimates, even though the underlying population did not suddenly decline. Because of the revised M, the 2025 assessment's long-term average biomass is about a third lower than the 2022 update's average; this reflects an improved understanding of the stock rather than a real-time drop in the stock itself.
The 2025 update shows that the biomass of age-1+ menhaden is just below its 20-year average but has been trending up since 2021.
Adult abundance in 2023 was 14.8 billion age-1+ fish, above the average of the past 20 years.
Recruitment in 2023 was 44.5 billion age-0 fish, above the average of the past 20 years.
With 64% of U.S. executives planning to change roles within the next three years, LHH expands its client solutions with its new US Retained Executive Search Practice designed to help organizations secure the leaders who will shape the future of work.
Read MoreJaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia®
A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals
Read More
Led by Menlo Ventures, with participation Sequoia Capital, and Cyberstarts, Zafran is doubling its valuation since the last round to advance the mission of stopping vulnerability exploitation everywhere
Read MoreLaing's appointment to support industrywide adoption of the IEEE 802.16t ("dot16") protocol, pioneered by Ondas Networks and selected by AAR as the upgrade path for network modernization and mission-critical rail communications in North America
Veteran Class I engineering leader with prior executive roles at Canadian Pacific Railway and Canadian National joins Ondas Networks Board
Laing was the 2023 RT&S Engineer of the Year, currently serves on AREMA's Board of Governors
Read More
- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®-
- New Synthetic Process to be Used for Phase 3 Development Provides Higher Manufacturing Yields and Reduces Costs Versus Naturally Harvested Halneuron® -
Read More
Highlights
(Unless otherwise noted, all financial amounts in this news release are expressed in U.S. dollars. IBC is reporting the performance of "continuing operations" at its Copper Alloy division, "discontinued operations" at its Massachusetts facility, and a combination of continuing and discontinued operations.1
The operating loss from continuing operations in the quarter improved from $226,000 to $67,000.
On a consolidated basis, Adjusted EBITDA for the quarter of ($55,000) compared favorably to adjusted EBITDA1 of ($449,000) in the prior year quarter. IBC recorded a loss of $702,000, which compared favorably to a loss in the prior-year quarter of $1.2 million.
Sales of $4.2 million for the quarter ended September 30, 2025 declined by 14.8% year-over-year (YOY).